Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/29/2021 07/30/2021 08/02/2021 08/03/2021 08/04/2021 Date
6.63 6.6 6.69 6.84 6.92 Last
77101400 59463640 50298070 58723390 55952180 Volume
+2.16% -0.45% +1.36% +2.24% +1.17% Change
Estimated financial data (e)
Sales 2021 34 259 M 4 405 M 4 405 M
Net income 2021 6 232 M 801 M 801 M
Net cash position 2021 9 842 M 1 266 M 1 266 M
P/E ratio 2021 21,1x
Yield 2021 1,20%
Sales 2022 41 532 M 5 340 M 5 340 M
Net income 2022 6 418 M 825 M 825 M
Net cash position 2022 14 789 M 1 902 M 1 902 M
P/E ratio 2022 21,1x
Yield 2022 1,21%
Capitalization 129 B 16 582 M 16 580 M
EV / Sales 2021 3,48x
EV / Sales 2022 2,75x
Nbr of Employees 24 262
Free-Float 52,4%
More Financials
Company
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of ophthalmia and hepatitis. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.4%); - other (2.6%). 
Sector
Pharmaceuticals
Calendar
08/25Earnings Release
More about the company
Ratings of Sino Biopharmaceutical Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SINO BIOPHARMACEUTICAL LIMITED
08/04AKESO : New Drug Application for Cancer Therapy Accepted in China
MT
08/02SINO BIOPHARMACEUTICAL : Biopharm's Hypertension Drug Wins Marketing Approval in..
MT
07/30SINO BIOPHARMACEUTICAL : Biopharm's Neuroprotective Agent Wins Registration Appr..
MT
07/29Sino Biopharmaceutical Limited Announces "Edaravone Injection" Obtains Drug R..
CI
07/28SINO BIOPHARMACEUTICAL : Biopharm's Antidepressant Wins Registration Approval in..
MT
07/27Sino Biopharmaceutical Limited commences an Equity Buyback Plan for 1,886,149..
CI
07/27SINO BIOPHARMACEUTICAL : China Approves Sino Biopharm's Liver Cancer Drug
MT
07/26SINO BIOPHARMACEUTICAL : Voluntary announcement - "lenvatinib mesilate capsule" ..
PU
07/26Sino Biopharmaceutical Limited Announces Lenvatinib Mesilate Capsule Has Obta..
CI
07/22SINO BIOPHARMACEUTICAL : Donates Cash and Supplies Valued at RMB10 Million to Su..
AQ
07/16SINO BIOPHARMACEUTICAL : Biopharm's Antiemetic Wins Registration Approval, Passe..
MT
07/16SINO BIOPHARMACEUTICAL : Biopharm's Intravenous Anesthetic Drug Wins Registratio..
MT
07/15Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injec..
CI
07/14HANG SENG : Hong Kong Hang Seng Down 0.6% on Wall Street Cues, China Growth Outl..
MT
07/02SINO BIOPHARMACEUTICAL : China Accepts New Drug Application for Lung Cancer Drug..
MT
More news
News in other languages on SINO BIOPHARMACEUTICAL LIMITED
05/25MÄRKTE ASIEN/Börsen steigen mit schwindenden Zinsängsten
05/25MÄRKTE ASIEN/Technologiewerte führen Börsen an
03/25MÄRKTE ASIEN/Börsen mit leichten Gewinnen - Tokio fest
03/10MÄRKTE ASIEN/Uneinheitlich - Verluste in Seoul und Sydney
03/10MÄRKTE ASIEN/Erholungsgewinne bröckeln im Verlauf ab
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 6,92 HKD
Average target price 11,19 HKD
Spread / Average Target 61,7%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-7.73%16 703
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613